A clinical pharmacological study of HP-3150 in patients with low back pain

Hisamitsu Pharmaceutical Co., Inc.1 个研究点目标入组 32 人开始时间: 待定最近更新: 2023年6月25日

试验速览

暂无简介。

研究类型: Interventional
干预模型: Multicenter, open-label, active-controlled, randomized, parallel-group comparison
主要目的: Other

•A patient who has received the following medications or has received the following therapies within 1 week prior to the study:
•(1) Diclofenac formulation
•(2) Application of topical agents to the upper arm or lumbar region
•(3) Nerve blockers, local anesthesia, or trigger point injection to the lumbar region
•(4) Aspirin
•A patient who has received drugs or cholestyramine within 4 weeks prior to the study that may have an interaction with diclofenac.
•A patient who has a history of surgical intervention for low back pain.
•A patient with concomitant rheumatoid arthritis.
•A patient with serious blood abnormality, liver disorder, renal disorder, hypertension, cardiac dysfunction, or other clinically problematic complications.
•A patient with malignancy.
•A patient with peptic ulcer.
•A patient with current or past history of aspirin-induced asthma.
•A patient with past history of hypersensitivity to NSAIDs.
•A patient who is pregnant, parturient, suspected of being pregnant, or breast-feeding.
•A patient who is known to have dermal sensitivity to external preparations or tapes such as adhesive tapes.
•A patient whose body hair does not allow patch to be secured to the application area.
•A patient in whom a planned site of application cannot be secured due to skin abnormality, tattoos or birthmarks, or a patient who frequently gets tanned.

pharmacokinetics - Drug concentration in tissue and plasma

发起方

Loading locations...